









Markets
/
Stocks
/
nasdaq-ocul
/

Ocular Therapeutix Inc

OCUL

9.160USD

+0.250+2.81%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.98BMarket Cap

LossP/E TTM



Ocular Therapeutix Inc

9.160

+0.250+2.81%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ocular Therapeutix Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ocular Therapeutix Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.92.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ocular Therapeutix Inc's Score

Industry at a Glance

Industry Ranking

54 / 159

Overall Ranking

162 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ocular Therapeutix Inc Highlights

StrengthsRisks

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Growing

The company is in a growing phase, with the latest annual income totaling USD 51.95M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 51.95M.

Fairly Valued

The company’s latest PE is -6.45, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 193.06M shares, increasing 12.03% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 42.37K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

24.917

Target Price

+179.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ocular Therapeutix Inc is 6.73, ranking 141 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 13.25M, representing a year-over-year decrease of 22.43%, while its net profit experienced a year-over-year decrease of 33.62%.

Score

Industry at a Glance

Previous score

6.73

Change



Financials

8.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.20

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ocular Therapeutix Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ocular Therapeutix Inc is 6.61, ranking 119 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -6.45, which is -62.97% below the recent high of -2.39 and -74.17% above the recent low of -11.23.

Score

Industry at a Glance

Previous score

6.61

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 54/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Ocular Therapeutix Inc is 8.77, ranking 9 out of 159 in the Pharmaceuticals industry. The average price target is 22.50, with a high of 31.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.77

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

24.667

Target Price

+188.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Ocular Therapeutix Inc

OCUL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ocular Therapeutix Inc is 6.75, ranking 110 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 12.01 and the support level at 7.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.252

Sell

RSI(14)

35.022

Neutral

STOCH(KDJ)(9,3,3)

21.051

Buy

ATR(14)

0.698

Low Volatility

CCI(14)

-70.557

Neutral

Williams %R

77.131

Sell

TRIX(12,20)

-1.119

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

8.856

Buy

MA10

9.539

Sell

MA20

10.282

Sell

MA50

11.823

Sell

MA100

11.759

Sell

MA200

10.930

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ocular Therapeutix Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 90.62%, representing a quarter-over-quarter increase of 22.96%. The largest institutional shareholder is The Vanguard, holding a total of 11.54M shares, representing 5.30% of shares outstanding, with 1.19% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

30.97M

+66.78%

VR Adviser, LLC

13.16M

+3.13%

Summer Road, LLC

12.13M

-3.54%

Deep Track Capital LP

11.93M

-16.53%

The Vanguard Group, Inc.

Star Investors

9.14M

+9.14%

Avoro Capital Advisors LLC

10.25M

+38.51%

BlackRock Institutional Trust Company, N.A.

9.23M

-1.20%

TCG Crossover Management, LLC

6.12M

+15.00%

Citadel Advisors LLC

5.70M

+16.74%

Point72 Asset Management, L.P.

Star Investors

4.60M

+141.64%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ocular Therapeutix Inc is 5.26, ranking 72 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.